Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovorafenib in Pediatric Low-Grade Gliomas and RAS/RAF/MEK/ERK Pathway Activated Tumors
NCT03429803Phase 1Completed
- Start
- Feb 2018
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of tovorafenib in glioma and solid tumor (2 arms). Primary endpoint: Dose Limiting Toxicity. Started Feb 2018; status: completed.
02
Drugs
tovorafenib
03
Conditions
gliomasolid tumor
Beyond the preview
Go deeper on NCT03429803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03429803.